. 2025 Nov 27;16:1728721. doi: 10.3389/fphar.2025.1728721

TABLE 4.

Comparison of MG-ADL, QMG, and MGC scores at different time points before treatment and at 1, 3, 6, and 12 months after ofatumumab treatment in 5 MuSK antibody-positive patients and 9 AChR antibody-positive patients.

	Variable	MuSK-Ab (+)	AChR-Ab (+)	P-value
	Variable	(n = 5)	(n = 9)	P-value
Baseline	MG-ADL	12.60 ± 5.59	11.00 ± 4.74	0.580^a
	QMG	18.00 ± 7.58	15.67 ± 5.63	0.523^a
	MGC	16.80 ± 9.26	10.89 ± 7.01	0.201^a
1 Month	MG-ADL	7.80 ± 4.55	4.67 ± 3.39	0.167^a
	QMG	8.80 ± 6.76	7.56 ± 3.43	0.651^a
	MGC	9.60 ± 6.88	5.89 ± 3.82	0.212^a
3 Months	MG-ADL	4.00 ± 1.87	2.89 ± 2.09	0.343^a
	QMG	5.00 ± 3.67	5.67 ± 3.81	0.756^a
	MGC	5.80 ± 4.82	3.67 ± 2.78	0.308^a
6 Months	MG-ADL	2.00 (2.00, 2.00)	2.00 (0.00, 6.00)	0.525^b
	QMG	2.80 ± 2.39	4.67 ± 4.15	0.379^a
	MGC	4.00 ± 4.42	3.33 ± 2.92	0.738^a
12 Months	MG-ADL	1.20 ± 0.84	1.44 ± 1.59	0.757^a
	QMG	2.00 ± 1.87	3.33 ± 3.12	0.405^a
	MGC	3.60 ± 4.04	3.44 ± 2.70	0.932^a

MuSK, Muscle-specific receptor tyrosine kinase; AChR, acetylcholine receptor; MG-ADL, myasthenia gravis activities of daily living; QMG, quantitative myasthenia gravis score; MGC, Myasthenia Gravis Composite. a: independent-samples t-test; b: Mann–Whitney U test. All tests are two-sided with α = 0.05; p < 0.001 is reported as “<0.001.” Statistically significant results (p < 0.05) are shown in bold.